US5616608A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
Assignee: United States Department of Health and Human Services
•
Filing: 1996-04-18
•
Granted: 1997-04-01
•
Expires: 2016-04-18
Abstract
Abstract The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.
Inventors
- 👤 James L. Kinsella
- 👤 Steven J. Sollott
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 17:03
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/337; A61L; A61L31/00; A61L31/14; A61L31/16; A61P; A61P3/00; A61P3/08; A61P3/10; A61P9/00; A61P9/10; A61P9/12; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/602
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
46 words
A method of preventing or reducing a fibroproliferative vascular disease in a patient comprising: treating said patient with a pharmaceutical preparation comprising a therapeutically effective amount of a microtubule stabilizing agent selected from the group consisting of taxol, a water soluble taxol derivative, and deuterium oxide.
Claim 2
Independent Claim
46 words
A method of preventing or reducing a fibroproliferative vascular disease in a patient comprising: treating said patient with a pharmaceutical preparation comprising a therapeutically effective amount of a microtubule stabilizing agent selected from the group consisting of taxol, a water soluble taxol derivative, and deuterium oxide.
Claim 3
Independent Claim
38 words
The method of 1 wherein said water soluble taxol derivative is selected from the group consisting of a 2'-succinyl-taxol; 2'succinyl-taxol triethanolamine 2'- glutaryltaxol; 2'- glutaryl-taxol trienthanolamine salt; 2'-O-ester with N-(dimethylaminoethyl) glutamide; and 2'-O-ester with N(dimethylaminoethyl) glutamide hydrochloride salt.
Claim 4
Independent Claim
38 words
The method of 1 wherein said water soluble taxol derivative is selected from the group consisting of a 2'-succinyl-taxol; 2'succinyl-taxol triethanolamine 2'- glutaryltaxol; 2'- glutaryl-taxol trienthanolamine salt; 2'-O-ester with N-(dimethylaminoethyl) glutamide; and 2'-O-ester with N(dimethylaminoethyl) glutamide hydrochloride salt.
Claim 5
Dependent Claim
11 words
The method of claim 1 wherein said vascular disease is atherosclerosis.
Claim 6
Dependent Claim
11 words
The method of claim 2 wherein said vascular disease is atherosclerosis.
Claim 7
Dependent Claim
11 words
The method of claim 1 wherein said vascular disease is restenosis.
Claim 8
Dependent Claim
11 words
The method of claim 2 wherein said vascular disease is restenosis.
Claim 9
Dependent Claim
18 words
The method of claim 1 wherein said treating step is comprised of systemic delivery of said pharmaceutical preparation.
Claim 10
Dependent Claim
18 words
The method of claim 1 wherein said treating step is comprised of local delivery of said pharmaceutical preparation.
Claim 11
Independent Claim
29 words
A method of preventing or reducing a fibroproliferative vascular disease in a patient comprising: treating said patient with a pharmaceutical preparation comprising a therapeutically effective amount of deuterium oxide.
Claim 12
Independent Claim
29 words
A method of preventing or reducing a fibroproliferative vascular disease in a patient comprising: treating said patient with a pharmaceutical preparation comprising a therapeutically effective amount of deuterium oxide.
Claim 13
Dependent Claim
11 words
The method of claim 9 wherein said vascular disease is atherosclerosis.
Claim 14
Dependent Claim
11 words
The method of claim 9 wherein said vascular disease is restenosis.
Claim 15
Dependent Claim
18 words
The method of claim 9 wherein said treating step is comprised of systemic delivery of said pharmaceutical preparation.
Claim 16
Dependent Claim
18 words
The method of claim 9 wherein said treating step is comprised of local delivery of said pharmaceutical preparation.
Claim 17
Dependent Claim
12 words
The method of claim 1 wherein said microtubule stabilizing agent is taxol.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-03-31 | 2000-09-30 | 2001-04-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-03-31 | 2004-09-30 | 2005-04-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-03-31 | 2008-09-30 | 2009-04-01 | $7700.00 | Window Closed / Lapsed |